RXST RxSight, Inc.
USHealthcareAs of 2026-07-10 12:32
Why RXST matters now
RxSight, Inc. (RXST) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.96 with -2.46% on the session and $205.1M in market capitalization; recent performance reads 1-month -20.50% and YTD -54.61%.
The latest financial table shown here is Q1 2026, with revenue of $30.9M, net income of $-15.9M, and EPS of $-0.38. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.0%.
The latest indexable market news headline is "Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $11.00; recent insider activity includes Andrews Julie filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.73
P/S
1.54
EV/EBITDA
-4.37
DCF Value
$-259.15
FCF Yield
-11.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.0%
Operating Margin
-43.4%
Net Margin
-36.6%
ROE
-17.0%
ROA
-15.3%
ROIC
-19.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $30.9M | $-15.9M | $-0.38 |
| Q4 2025 | $32.6M | $-9.2M | $-0.22 |
| FY 2025 | $134.5M | $-38.9M | $-0.95 |
| Q3 2025 | $30.3M | $-9.8M | $-0.24 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$10.33
Target (Median)
$11.00
Target Range
$9.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.13
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.